Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fostroxacitabine bralpamide - Medivir AB

Next Previous
Drug Profile

Fostroxacitabine bralpamide - Medivir AB

Alternative Names: Fostrox; MIV-818

Latest Information Update: 12 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Medivir AB
  • Class Antineoplastics; Bromobenzenes; Dioxolanes; Esters; Nucleotides; Organophosphorus compounds; Pyrimidines; Small molecules
  • Mechanism of Action DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Liver cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Liver cancer

Most Recent Events

  • 20 Feb 2025 Efficacy and safety data from a phase Ib/IIa trial in Liver cancer released by Medivir
  • 30 Dec 2024 Medivir completes a phase I/IIa trial for Liver cancer (Late-stage disease, Inoperable/Unresectable, Combination therapy) in South Korea, Spain, Belgium, United Kingdom (PO) (NCT03781934) (EudraCT2018-000995-14)
  • 30 Dec 2024 Medivir completes its phase I/IIa trial for Liver cancer (Late-stage disease, Inoperable/Unresectable, Monotherapy) in South Korea, Spain, Belgium, United Kingdom (PO) (NCT03781934) (EudraCT2018-000995-14)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top